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Abstract: The use of doping in sports is a global problem that affects athletes around the world. 
Among the different methods developed to detect doping agents in biological samples, there are 
antibody-based methods that need an appropriate hapten design. Steroids with a hydroxyl group 
can be converted to the corresponding hemisuccinates. A novel approach to the synthesis of 17β-O-
hemisuccinate of the common doping agent stanozolol is described here. Acylation of stanozolol 
with methyl 4-chloro-4-oxobutyrate/4-dimethylaminopyridine, followed by mild alkaline 
hydrolysis with methanolic sodium hydroxide at room temperature, gave the simultaneous 
protection and deprotection of pyrazole-nitrogen atoms. The proposed new synthetic method 
allows the desired hemisuccinate derivative to be obtained in only two steps, and with a good total 
yield starting from stanozolol. 
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1. Introduction 
Doping in competitive sports is a threat not only for ethics in sports but also for the athlete's 
health. The World Anti-Doping Agency (WADA) was founded to counteract this despicable practice, 
but there are some critical issues [1]. The problem of anti-doping tests has a changing legal face, as it 
touches forensic, health, and even agricultural regulations [2]. Cheap and ready-to-use methods are 
necessary for efficient control of anabolic–androgenic steroids (AAS) and similar compounds. The 
ideal method for screening of anabolic steroids should be fast, simple, cost-effective, easy to perform, 
and should enable measurement in a small volume of biological fluid [3]. Food safety and accredited 
WADA laboratories use HPLC-MS and GC-MS as the most common analytical methods to routinely 
control the use of these substances [4–8]. In addition, the literature presents a few other analytical 
methods that couple HPLC or GC techniques with immunochemical detection [9,10] and a 
chemiluminescent immunoassay method [11]. The analysis of anabolic steroids presents some 
difficulties related to their neutral and relatively nonpolar nature, together with the very low levels 
that must be detected and the high levels of naturally occurring steroids usually present in the 
samples. Antibody-based detection methods offer rapid, simple, and cost-effective alternatives for 
analytical measurements. They are one of the more sensitive assays available because of the high 
affinity of antibodies and fulfill most of the criteria suitable for routine high-throughput screening. 
In addition, an appropriate hapten design allows raising antibodies, obtained after immunization of 
selected animals, with tailored features and cross-reactivity patterns that make possible registering 
both the parent molecules and their metabolites simultaneously. For the purpose of immunization, 
an immunogen, a carrier protein with bound molecules of target steroid via a defined spacer, is used. 
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Steroids conjugated to macromolecules can elicit anti-steroid antibodies and serve as solid-phase 
antigens for the immunological detection of the hormones [12]. Different reactions are used to link 
these haptens to the macromolecular carrier, depending on the functional groups of the molecules. 
Condensation between carboxylic and amino groups is the most widely employed procedure, 
applicable also to compounds that do not possess these functional groups originally [13]. More 
specifically, steroids with a hydroxyl group can be converted to their corresponding hemisuccinates, 
with the hemisuccinate linker that represents one of the typically used spacers in this respect [14]. 
In the literature, there are several direct and indirect methods for the preparation of 
hemisuccinates. The usual synthesis of steroidal hemisuccinates by the direct method treats the 
corresponding alcohols with succinic anhydride in pyridine [15], at room or elevated temperature. 
This method, applied for example to testosterone, is focussed on the base catalysis of pyridine but 
cannot be applied to sensitive and reactive substrates [16]. Another direct method, not examined on 
steroids, employs anhydride and, as catalyst, bismuth triflate (Bi(OTf)3). The Bi(OTf)3/acid anhydride 
protocol was so powerful that sterically hindered or tertiary alcohols could be acylated [17]. Finally, 
the ability of hydrolases to accomplish one-step syntheses of specific steroid hemisuccinates was also 
investigated. In this respect, 3,17-β-estradiol was regioselectively acylated with succinic anhydride at 
the 17β-hydroxyl by the action of subtilisin Carlsberg in organic solvent [18]. 
Indirect methods for the synthesis of hemisuccinates of steroids bearing a tertiary alcohol group, 
use methylmagnesium bromide to form a steroidal alkoxide and, methyl succinyl chloride as an 
acylating reagent. The corresponding hemisuccinate is then obtained by the hydrolysis of 
monomethyl ester [19]. Another indirect method, described only for hemisuccinate preparation of 
steroids bearing a secondary alcohol group, consists of the reaction of the steroidal alcohol with 4-
(2,2,2-trichloroethoxy)-4-oxobutanoic acid in benzene in the presence of N,N'-
dicyclohexylcarbodiimide (DCC) and 4-dimethylaminopyridine (DMAP) that affords the blocked 
ester formation, and the following release of the hemisuccinate at 0 °C with zinc powder in a 
tetrahydrofuran-acetic acid-water mixture [14]. 
Stanozolol (Stz; Scheme 1), first developed in 1959 [20], is one of the most important synthetic 
anabolic steroids used to increase human athletic performance, and as a growth promoter in cattle 
and horses for racing [21]. Several reports document its abuse by athletes to help build muscle mass, 
boost acceleration, and recover faster from workouts [22]. Beyond illegal uses, we should also recall 
that Stz has substantial fibrinolytic properties and has been effective in the treatment of serious 
disorders like the Raynaud phenomenon and cryptofibrinogenemia [23]. Other therapeutic uses of 
Stz include treatment of AIDS wasting syndrome [24], aplastic anemia, and hereditary angioedema 
[25]. It has also been indicated as an adjunct therapy for the treatment of vascular disorders and 
growth failures, which arise as a result of other medical conditions. Otherwise, the illicit use of AAS 
in nutritional supplements is a cause of concern [26], so it is crucial to monitor this group of 
substances. The common analytical methods for determination and quantification of AAS, their 
metabolites, and Stz and its major metabolites such as 3'-hydroxy-stanozolol, 3'-hydroxy-17-
epistanozolol, 4-hydroxy-stanozolol, or 16-hydroxystanozolol, in both powders or liquid matrices 
as urine samples, include GC-MS and LC-MS-MS based approaches [21,27]. On the other hand, like 
most other AAS, Stz has poor gas chromatographic behavior. Moreover, these methods require 
authentic standards, expensive instrumentation, and sample analysis needs expert operators and 
adequately equipped laboratories. In addition, low urinary excretion and renal clearance render these 
molecules difficult to be detected in urine samples leading to the need for very high sensitive 
analytical methods. This is due to the rapid metabolization, leading to low concentration levels of the 
parent compounds found in urine. Instead, ELISA (enzyme-linked immunosorbent assay) is a 
commonly used analytical assay, as it enables parallel analysis of multiple samples in a short time, 
utilizing a simple procedure, and appears to be a useful cost-effective screening tool for the 
preselection of suspect samples for further instrumental approaches, which are, however, 
irreplaceable in identification and quantification of particular steroids [28]. As previously reported, 
a carrier protein with bound molecules of the target steroid via a defined spacer is used to elicit anti-
histone antibodies [29]. This is also the case for Stz, where a specific derivative, with an appropriate 
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spacer, is necessary to build up an efficient antibody for the preparation of an ELISA kit for Stz and 
its metabolites analysis. 
Herein, we report on a new synthesis of 17β-O-hemisuccinate of Stz in only a two-step reaction 
with 55% overall yields. The simple use of methyl 4-chloro-4-oxobutyrate as the acylating agent to 
obtain hemisuccinates of steroid alcohols is, to our knowledge, unprecedented in the literature. 
2. Results and Discussion 
The analysis of anabolic steroids is of particular interest for their use both in farms for animal 
growth promotion and in sports, as AAS have been prohibited substances since 1976. Unfortunately, 
the analysis of AAS presents some complexities due to their chemical nature, together with the low 
levels in bio matrices due to the metabolism and the concomitant high level of natural steroids that 
often act as interfering agents. Moreover, to achieve efficient control of AAS, the knowledge of the 
metabolic pathway is mandatory, allowing us also to recognize metabolites. In particular, for Stz, the 
16-hydroxy-stanozolol (16-OH Stz) has been identified as the major urine metabolite in cattle [30] 
and humans [31,32]. In addition, 16-OH Stz is principally secreted as glucuronide or glucuronide of 
the sulfate conjugate, as often happens for Stz and other steroids. All these considerations highlight 
the importance of designing and producing the appropriate hapten to obtain, for analytical 
applications, antibodies able to recognize both parent molecules and their metabolites. 
Therefore compound 1, with a spacer arm at position 17β-OH, was designed to expose the 
pyrazole ring to the immune system. The selection of the pyrazole moiety, common in the Stz and 
16-OH Stz structures, as recognition region site will allow detection both Stz and its major urinary 
metabolite 16-OH Stz, not only in their natural form but also as glucuronide derivatives or 
glucuronide of the sulfate conjugates (Figure 1). 
 
Figure 1. Chemical structures of compound 1, Stz, 16-OH Stz, and their glucuronides derivatives. In 
light blue are indicated the expected recognition positions maintained in these chemical structures. 
With this premise, we addressed the preparation of compound 1 from Stz and exploited the 17β-
hydroxy group to introduce the linker hemisuccinate. 
As Stz has more than one reactive group is present on the molecule, the low regioselectivity of 
this transformation makes it necessary to introduce additional masking and unmasking steps. 
There are two reported examples for the synthesis of 17-O-hemisuccinate of Stz. The first one 
[33] passes through the synthesis of the oxymetholone hemisuccinate, achieved in two steps by the 
formation of the carbomethoxy butyrate at the 17-OH of the oxymetholone and the following 
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hydrolysis of the carbomethoxy moiety in mild alkaline conditions. Then, compound 1 is obtained 
from 3-ketosteroid by the introduction of a 2-formyl group at C-3, followed by condensation of the 
resulting 3-keto-aldehyde moiety of oxymetholone hemisuccinate with hydrazine hydrate. This first 
synthesis is a time-consuming procedure that requires four reaction steps, each followed by several 
crystallizations to isolate the pure intermediate, leading to poor final yields. In the second method 
[34], the pyrazole-nitrogen atoms have to be protected as Boc derivative in order to avoid its 
nucleophilic attack in the following step, i.e., the acylation of the 17β-hydroxy group. Then the 2’-Boc 
derivative is separated and subjected to reaction with 2-(trimethylsilyl)ethyl hydrogen butanedioate 
and ethyl-3-(3-dimethyl-aminopropyl)-1-carbodiimide hydrochloride (EDC) coupling reagent to give 
the Stz hemisuccinate. Finally, a microwave-assisted reaction was performed in tetrahydrofuran at 
high temperature and with an excess of TBAF to remove in one-step both 2’-Boc and trimethylsilyl 
protective groups. Following this second approach, it is worth mentioning that the protection with 
Boc, that gave two regioisomers in similar yields, and the next selection of the 2’-Boc isomer, leads 
unavoidably to the halving of the quantity of the final product. 
In order to obtain an easier and cheaper synthetic procedure, able to give good yields, we 
investigated the feasibility of reducing the number of reaction steps using succinate moiety as both 
protecting group, and spacer linker added respectively at the pyrazole-nitrogen atom and a hydroxyl 
group in position 17β of Stz. 
 
Scheme 1. Synthesis of Stz hemisuccinate (1): (a) methyl 4-chloro-4-oxobutyrate, DMAP, CH2Cl2; (b) 
NaOH, MeOH. 
It is known that pyrazole-nitrogen atoms are readily acylated, and it has been demonstrated that 
the N-acyl groups in O,N-diacyl steroid-[3,2-c] pyrazoles are sufficiently labile to be removed quite 
easily and selectively at room temperature [35]. Moreover, despite the inert character of tertiary 
alcohol in the 17 position, it is possibly the formation of the ester bond [12–14]. 
Herein, we report for the first time the transformation of Stz to desired stanozolol-17β-O-
hemisuccinate (1) in only two steps, as shown in Scheme 1. The structural assignment of the products 
was made by 1H-NMR spectroscopy. 
For the preparation of hemisuccinate 1, we focused right away on the direct method using, as 
acylating agent, methyl 4-chloro-4-oxobutyrate that, as far as we know, had never been used before 
for this purpose (Scheme 1). In the preliminary experiments to introduce succinyl group in the 
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reaction of Stz with methyl 4-chloro-4-oxobutyrate, we isolated a mixture of isomers, 2a and 2b, in 
an approximate 4:1 ratio, in accordance with the literature [36], that were not separated, as it was 
confirmed by 1H-NMR in Figure S1a and S1b (supplemental material). The 1H-NMR spectrum 
allowed us to distinguish between the two regioisomers. In particular, the shift of 5′ hydrogen of the 
pyrazole ring in the major isomer 2a, acylated in N-1′ position, was 7.91 ppm, whereas, for the 
regioisomer 2b, acylated in N-2′ position, the shift was lower, at 7.44 ppm. The deshifted 7.91 ppm in 
the case of isomer 2a was caused by the anisotropic effect of the succinyl substitute in the N-1′ 
position. The shift is less evident in the case of the isomer 2b, due to the distance of the succinate in 
N-2′ position compared to 5′-H. The identity of the two regioisomers was also confirmed because the 
presence of succinate in the pyrazole ring affected the hydrogens in 1-H and 4-H positions of the 
steroidic ring. In fact, if in the isomer 2a the 1-H and 4-H shifts are substantially unchanged compared 
to the shifts of the analogous hydrogens in Stz, in the isomer 2b the 4-H shift is deshifted from 2.61 
to 3.08 ppm and the 4-H from 2.28 to 2.48 ppm, due to the closeness of succinate. All spectra and 
the comparative spectra of mixture 2a/2b are reported in the Supplemental Material Figure S1a and 
1bS. 
Without intermediates 2a and 2b isolation and purification, the two successive additions of the 
same quantities (1.33 eq each) of methyl 4-chloro-4-oxobutyrate after 24 and 48 h gave the compounds 
3a and 3b. In spite of the inert character of the tertiary alcohol in the 17β position, we were able to 
obtain the ester in this hindered position. The 1H-NMR spectrum of the mixture confirmed the 
introduction of a second succinate moiety (Supplemental Material). 
Subsequent treatment of 3a and 3b mixture with NaOH in methanol at room temperature gave 
first the methyl steroid succinate (4), not isolated, and then the derivative 1 [19]. In compound 4, the 
removal of the succinate from the two regioisomers was confirmed with the NMR spectrum, where 
it was observed that the shift of 5′-H, 1-H, and 4-H were at the same position of Stz. 
Compounds 2a and 2b and 4 have only been isolated and purified once for the deep NMR 
characterization to study the intermediates of the reaction that lead to the final product. Thus, by 
means of this sequence of only two reaction steps, we were able to obtain excellent overall yields 
(55%) of desired Stz hemisuccinate (1). 
3. Material and Methods 
3.1. Chemistry 
Chemicals, solvents, and standards were obtained from Sigma–Aldrich (Merck, Darmstadt, 
Germany) and used without further purification. Stanozolol was purchased from Steraloids 
(Steraloids Inc., Newport, RI, USA). Column chromatography was performed on Silica Gel 60 (70–
230 mesh) using the specified eluents. The progress of the reactions was monitored by analytical thin-
layer chromatography (TLC) on pre-coated glass plates (silica gel 60 F254-plate-Merck, Darmstadt, 
Germany) and the products were visualized by UV light. The purity of all compounds (>99%) was 
verified by thin-layer chromatography and NMR measurements [37–40]. 
3.2. NMR Analysis 
NMR spectra were registered on a Bruker AVANCE 500 spectrometer (Bruker Italia Srl, Milan, 
Italy) equipped with a 5-mm broadband reverse probe and deuterium lock with field z-gradient 
operating at 500.13 and 125.76 MHz for 1H and 13C, respectively. All NMR spectra were recorded at 
298 K in CDCl3 (isotopic enrichment 99.98%) solution, and the chemical shifts were reported on a  
(ppm) scale. The central peak of DMSO-d6 signals (2.49 ppm for 1H and 39.50 ppm for 13C) and of 
CDCl3 signals (7.28 ppm for 1H and 77.7 ppm for 13C) were used as the internal reference standard. 
Acquisition parameters for 1D were as follows: 1H spectral width of 5000 Hz and 32 K data points 
providing a digital resolution of ca. 0.305 Hz per point, relaxation delay 2 s; 13C spectral width of 
29412 Hz and 64 K data points providing a digital resolution of ca. 0.898 Hz per point, relaxation 
delay 2.5 s. The experimental error in the measured 1H-1H coupling constants was ± 0.5 Hz. 
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3.3. Synthesis of Compound 3  
To a suspension of Stz (200 mg, 0.6 mmol) and dimethylaminopyridine in anhydrous 
dichloromethane (5 mL), methyl-4-chloro-4-oxo-butyrate (100 μl, 0.8 mmol) was slowly added. Two 
successive portions of the same quantity of methyl-4-chloro-4-oxo-butyrate were added after 24 h 
and 48 h, and stirring was continued until the completion of the reaction (overall 72 h). The reaction 
was monitored by TLC (dichloromethane/ methanol 95:5). The mixture was poured in water and 
extracted with dichloromethane (3 × 5 mL), and the extracts were washed with HCl 0.1 M. The 
solution was then concentrated under vacuum, and hexane was added. The precipitate was separated 
by filtration on celite, and the residue was evaporated, giving 300 mg of an uncolored oil (0.54 mmol, 
yield 90%). 
To verify the identity of intermediates 2a and 2b by NMR, the reaction was stopped after 2 h, 
and the mixture was separated on column chromatography on silica gel (petroleum ether/ethyl 
acetate 7:3). 
Mixture 2a and 2b: Rf 0.7 (dichloromethane/methanol 95:5); 1H NMR (CDCl3) major regioisomer 
2a: δ 7.91 (1H, s, 5′-H), 3.72 (3H, s, COOCH3), 3.41 (2H, t, J = 6.5 Hz, NCOCH2CH2COOCH3), 2.78 (2H, 
t, J = 6.5 Hz, NCOCH2CH2COOCH3), 2.71 (1H, d, J = 15.4 Hz, 1β-H), 2.68 (1H, dd, J = 12.2, 2.0 Hz, 4β-
H), 2.33 (1H, dd, J = 12.2, 2.0 Hz, 4α-H), 2.15 (1H, d, J = 15.4 Hz, 1α-H), 1.28 (3H, s, 20-CH3), 0.89 (3H, 
s, 19-CH3), 0.79 (3H, s, 18-CH3); minor regioisomer 2b: δ 7.44 (1H, s, 5′-H), 3.73 (3H, s, COOCH3), 3.46 
(2H, t, J = 6.5 Hz, NCOCH2CH-COOCH3), 3.08 (1H, dd, J = 12.2, 2.0 Hz, 4β-H), 2.76 (2H, t, J = 6.5 Hz, 
NCOCH2CH2COOCH3), 2.53 (1H, d, J = 15.4 Hz, 1β-H), 2.48 (1H, dd, J = 12.2, 2.0 Hz, 4α-H), 2.07 (1H, 
d, J = 15.4 Hz, 1α-H), 1.25 (3H, s, 20-CH3), 0.89 (3H, s, 19-CH3), 0.76 (3H, s, 18-CH3) 
Mixture 3a and 3b: Rf 0.9 (dichloromethane/methanol 95:5); 1H NMR (CDCl3) major regioisomer 
3a: δ 7.91 (1H, s, 5′-H), 3.72 and 3.70 (6H, s, 2 × COOCH3), 3.41 (2H, t, J = 6.5 Hz, NCOCH2CH2-
COOCH3), 2.78 (2H, t, J = 6.5 Hz, NCOCH2CH2COOCH3), 2.71 (1H, d, J = 15.4 Hz, 1β-H), 2.68 (1H, dd, 
J = 12.2, 2.0 Hz, 4β-H), 2.66–2.52 (4H, m, NCOCH2CH2COO), 2.33 (1H, dd, J = 12.2, 2.0 Hz, 4α-H), 2.07 
(1H, d, J = 15.4 Hz, 1α-H), 1.27 (3H, s, 20-CH3), 0.87 (3H, s, 19-CH3), 0.77 (3H, s, 18-CH3); minor 
regioisomer 3b: δ 7.44 (1H, s, 5′-H), 3.73 and 3.70 (6H, s, 2 × COOCH3), 3.45 (2H, t, J = 6.5 Hz, 
NCOCH2CH2-COOCH3), 2.76 (2H, t, J = 6.5 Hz, NCOCH2CH2COOCH3), 2.66–2.52 (5H, m, 
NCOCH2CH2COO and 1β-H), 2.48 (1H, dd, J=12.2, 2.0 Hz, 4β-H), 2.33 (1H, dd, J = 12.2, 2.0 Hz, 4α-H), 
2.07 (1H, d, J = 15.4 Hz, 1α-H), 1.27 (3H, s, 20-CH3), 0.87 (3H, s, 19-CH3), 0.75 (3H, s, 18-CH3). 
3.4. Synthesis of 17β-O-hemisuccinate of Stanozolol (1) 
To a solution of 3a/3b in methanol (3 mL) powdered NaOH was added in three portions of 20 
mg each during 48 h. Stirring at room temperature was continued for other 24 h (overall 72 h). After 
TLC (dichloromethane/methanol 95:5) the resulting precipitate was collected under vacuum as a 
white solid (140 mg). The solid was resuspended in methanol and acidic resin (Dowex 50W × 8) was 
added (20 mg). After 24 h at room temperature under stirring, filtration and evaporation of the 
solvent gave 140 mg of product as white solid (0.3 mmol, overall yield 55%). 
Only to perform NMR analysis, compound 4 was isolated by column chromatography on silica 
gel (dichloromethane/methanol 95:5), after 1 h. 
Compound 4: Rf 0.5 (dichloromethane/methanol 95:5); 1H NMR (CDCl3) δ 7.32 (1H, s, 5′-H), 3.71 
(3H, s, COOCH3), 2.64 (1H, d, J = 15.4 Hz, 1β-H), 2.66–2.57 (5H, m, NCOCH2CH2COO and 4β-H), 2.30 
(1H, dd, J = 12.2, 2.0 Hz, 4α-H), 2.11 (1H, d, J = 15.4 Hz, 1α-H), 1.28 (3H, s, 20-CH3), 0.88 (3H, s, 19-
CH3), 0.78 (3H, s, 18-CH3). 
Compound 1: Rf 0.1 (dichloromethane/methanol 95:5), mp 218–220 °C (from MeOH) (lett. 215–
217 °C [33]). 1H-NMR (DMSO-d6): δ 7.23 (1H, s, 5′-H), 3.58 (1H, s, NH); 2.55–2.40 (6H, m, 
OCOCH2CH2COOH, 1β-H and 4β-H), 2.14 (1H, dd, J = 12.2, 2.0 Hz, 4α-H), 2.05 (1H, d, J = 15.4 Hz, 
1α-H), 1.35 (3H, s, 17-CH3), 0.82 (3H, s, 18-CH3), 0.68 (3H, s, 19-CH3). 13C-NMR (DMSO-d6): δ 173.9 
(COOH), 171.5 (OCOCH2), 141.5 (C-3), 131.6 (C-5′), 113.6 (C-2), 90.7 (C-17), 53.4, 51.8, 48.8, 46.5, 42.5, 
36.6, 36.3, 35.0, 32.2, 31.6, 30.2, 29.4 (-OCOCH2CH2COOH), 29.3 (-OCOCH2CH2COOH), 26.7, 23.8, 21.6 
(CH3-17), 20.7 (C-11), 14.6 (C-19), 11.8 (C-18). 
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4. Conclusions 
To summarize, we propose here an alternative procedure for the synthesis of 17β-O-
hemisuccinate of stanozolol (1). The new approach involves a sequence of two simultaneous 
transformations without a preventive protection of the highly reactive pyrazole-nitrogen atoms. 
Indeed in the first step, stanozolol is transformed in the disuccinate 3a,b then, in a one-pot reaction, 
the successive treatment with NaOH/MeOH gives the simultaneous deprotection of the pyrazole ring 
and the hydrolysis of the 17β-methyl ester. Our method gives good yields and has the advantage that 
tedious purification and isolation of the intermediates are not necessary. 
Supplementary Materials: The following are available online, Figure S1a. 1H-NMR spectrum from 8.40 ppm to 
6.00 ppm of Stanozolol (top) and mixture 2a/2b (bottom). Figure S1b. 1H-NMR spectrum from 4.20 ppm to 2.00 
ppm of Stanozolol (top) and mixture 2a/2b (bottom). 
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